Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Swaminathan P Iyer"'
Autor:
Susan Y. Wu, MD, Penny Q. Fang, MD, MBA, Ethan B. Wang, BA, Sairah Ahmed, MD, Madeleine Duvic, MD, Preetesh Jain, MD, Luis E. Malpica Castillo, MD, Ranjit Nair, MD, Raphael E. Steiner, MD, Paolo Strati, MD, Auris O. Huen, MD, PharmD, Swaminathan P. Iyer, MD, Chelsea C. Pinnix, MD, PhD, Bouthaina S. Dabaja, MD, Jillian R. Gunther, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 6, Pp 101279- (2023)
Purpose: Purpose: Radiation therapy (RT) and the antibody-drug conjugate brentuximab vedotin (BV) are standard-of-care treatment options for patients with certain B and T-cell lymphomas; however, there are limited data exploring the safety of concurr
Externí odkaz:
https://doaj.org/article/d902d9f49c7047199b12871407803f0e
Autor:
Daniela Santiesteban, Aundrietta D. Duncan, Nadeem Q. Mirza, Stephen Horrigan, Sheila Dewitt, Vincent Jacques, Swaminathan P. Iyer
Publikováno v:
HemaSphere, Vol 7, p e95971dd (2023)
Externí odkaz:
https://doaj.org/article/84cc5aa832f14e99bfcc36a5048a2ec2
Autor:
Swaminathan P. Iyer, Auris Huen, Weiyun Z. Ai, Deepa Jagadeesh, Mary J. Lechowicz, Craig Okada, Tatyana A. Feldman, Paola Ghione, Juan P. Alderuccio, Rebecca Champion, Seo-Hyun Kim, Ann Mohrbacher, Kasi V. Routhu, Prajak Barde, Ajit M. Nair, Bradley M. Haverkos
Publikováno v:
Haematologica, Vol 109, Iss 1 (2023)
Tenalisib, a selective phosphoinositide-3-kinase δ/γ, and salt-inducible-kinase-3 inhibitor has shown efficacy and was well-tolerated in patients with T-cell lymphoma (TCL). In vitro studies suggest a synergistic anti-tumor potential for the combin
Externí odkaz:
https://doaj.org/article/e5c3577369044e1e834302358c57d097
Autor:
Christopher N. Nguyen, BA, Swaminathan P. Iyer, MD, Roberto N. Miranda, MD, Carlos A. Torres-Cabala, MD, Jonathan L. Curry, MD, Penny Fang, MD, Valencia D. Thomas, MD, Auris O. Huen, MD
Publikováno v:
JAAD Case Reports, Vol 17, Iss , Pp 34-37 (2021)
Externí odkaz:
https://doaj.org/article/29f780d90c1a4722916fc4eea6d73f95
Autor:
Lianqun Qiu, Guilin Tang, Shaoying Li, Francisco Vega, Pei Lin, Sa A. Wang, Wei Wang, Swaminathan P. Iyer, Luis Malpica, Roberto N. Miranda, Sergej Konoplev, Zhenya Tang, Hong Fang, L. Jeffrey Medeiros, Jie Xu
Publikováno v:
Haematologica, Vol 108, Iss 6 (2022)
DUSP22 rearrangement (R) has been associated with a favorable outcome in systemic ALK-negative anaplastic large cell lymphoma (ALCL). However, a recent study found that patients with DUSP22-R ALK-negative ALCL have a poorer prognosis than was reporte
Externí odkaz:
https://doaj.org/article/a763fe98c02c4048a9982e29e7e51964
Autor:
Andrew P. Jallouk, Sushanth Gouni, Jason Westin, Lei Feng, Haleigh Mistry, Raphael E. Steiner, Jinsu James, Mansoor Noorani, Sandra Horowitz, Nahum Puebla-Osorio, Luis E. Fayad, Swaminathan P. Iyer, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta J. Nastoupil, Partow Kebriaei, Elizabeth J. Shpall, Sattva S. Neelapu, Yago Nieto, Paolo Strati
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/e594de9ca2264723b1d6eb36952f069d
Autor:
Mario L. Marques-Piubelli, Luisa M. Solis, Edwin R. Parra, Luis Malpica Castillo, Sushanth Gouni, Ranjit Nair, Dai Chihara, Marina Konopleva, Ignacio I. Wistuba, Swaminathan P. Iyer, Francisco Vega, Paolo Strati
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/6130830d682f4eefbb3bb5566d89c087
Autor:
Taylor C. Duke, MD, Ranjit Nair, MD, Carlos Torres-Cabala, MD, Rodabe N. Amaria, MD, Elizabeth Keiser, MD, Roberto Miranda, MD, Swaminathan P. Iyer, MD, Meghan Heberton, MD
Publikováno v:
JAAD Case Reports, Vol 6, Iss 12, Pp 1264-1267 (2020)
Externí odkaz:
https://doaj.org/article/ad82ea49a92c40879ff2c5dc18cfbd1b
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1124-1133 (2020)
This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancie
Externí odkaz:
https://doaj.org/article/cc393339519a45dc9eb5637a36459980
Publikováno v:
Leukemia Research Reports, Vol 17, Iss , Pp 100292- (2022)
Large granular lymphocytic leukemia (LGL) is a rare lymphoproliferative disorder that involves the T-cell lineage in around 85% of cases and NK-cell lineage in 15%. Most patients require treatment at some point of their disease trajectory to address
Externí odkaz:
https://doaj.org/article/667c539f98c94bc3a31bbc106d1b538e